TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$249,975.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
N43CA130059
Agency Tracking Number:
N43CA130059
Solicitation Year:
2013
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
ROCKLAND IMMUNOCHEMICALS, INC.
650 ENGLESVILLE ROAD, BOYERTOWN, PA, 19512-
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
58999129
Principal Investigator:
CARL ASCOLI
(800) 656-7625
CARL.ASCOLI@ROCKLAND-INC.COM
Business Contact:
CARL ASCOLI
(800) 656-7625
CARL.ASCOLI@ROCKLAND-INC.COM
Research Institution:
Stub




Abstract
Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I proposal, high-affinity camelid single domain antibodies to three cancer biomarkers HER2, EGFR and mesothelin will be developed. The antibodies will be directionally conjugated to near-infrared spectrum fluorescentdyes. Properties of the nanobody, including in vivo clearance, rapid tumor accumulation, in vivo stability and bioavailability, will be investigated in tumor xenograft animal models. In the Phase II, selected antibodies will be conjugated with chelators for radiolabeling with metal radionuclides. Pharmacokinetic, pharmacodynamics, immunogenic and toxicological characteristics of agents will be investigated in animal models to obtain data necessary for filing an Investigational New Drug application. PUBLIC HEALTH RELEVANCE

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government